9CDL
 
 | | SARS-CoV-2 Mpro E166V/L50F double mutant in complex with small molecule inhibitor Mpro61 | | Descriptor: | (5P)-5-[(1P,3M,3'P)-3-{3-chloro-5-[(2-chlorophenyl)methoxy]-4-fluorophenyl}-2-oxo-2H-[1,3'-bipyridin]-5-yl]-1-methylpyrimidine-2,4(1H,3H)-dione, 3C-like proteinase nsp5 | | Authors: | Tang, S, Kenneson, J.R, Huynh, K, Anderson, K.S. | | Deposit date: | 2024-06-25 | | Release date: | 2025-02-05 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (1.52 Å) | | Cite: | Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M pro ) with Noncovalent Preclinical Candidate, Mpro61.
Acs Bio Med Chem Au, 5, 2025
|
|
9CDM
 | | SARS-CoV-2 Mpro L50F mutant in complex with small molecule inhibitor Mpro61 | | Descriptor: | (5P)-5-[(1P,3M,3'P)-3-{3-chloro-5-[(2-chlorophenyl)methoxy]-4-fluorophenyl}-2-oxo-2H-[1,3'-bipyridin]-5-yl]-1-methylpyrimidine-2,4(1H,3H)-dione, 3C-like proteinase nsp5, DIMETHYL SULFOXIDE | | Authors: | Tang, S, Kenneson, J.R, Huynh, K, Anderson, K.S. | | Deposit date: | 2024-06-25 | | Release date: | 2025-02-05 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.05 Å) | | Cite: | Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M pro ) with Noncovalent Preclinical Candidate, Mpro61.
Acs Bio Med Chem Au, 5, 2025
|
|
9G9C
 | |
9G9D
 | |
8XSD
 | | BA.5 Spike complex with CR9 | | Descriptor: | CR9 heavy chain, CR9 light chain, Spike glycoprotein | | Authors: | Feng, L.L. | | Deposit date: | 2024-01-09 | | Release date: | 2025-02-12 | | Last modified: | 2025-07-02 | | Method: | ELECTRON MICROSCOPY (3.55 Å) | | Cite: | A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5.
Signal Transduct Target Ther, 10, 2025
|
|
8Y42
 | | Crystal structure of SARS-CoV-2 3CL protease (3CLpro) in complex with compound 51 | | Descriptor: | 3C-like proteinase nsp5, ~{N}-[(1~{S},2~{R})-2-[[4-cyclopropyl-2-(methylcarbamoyl)-6-nitro-phenyl]amino]cyclohexyl]-2-oxidanylidene-1~{H}-quinoline-4-carboxamide | | Authors: | Nie, T.Q, Su, H.X, Li, M.J, Xu, Y.C. | | Deposit date: | 2024-01-30 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-26 | | Method: | X-RAY DIFFRACTION (2.35 Å) | | Cite: | Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CL pro Inhibitors as anti-SARS-CoV-2 Drug Candidate.
J.Med.Chem., 67, 2024
|
|
8Y44
 | | Crystal structure of SARS-CoV-2 3CL protease (3CLpro) in complex with compound 44 | | Descriptor: | 3C-like proteinase nsp5, ~{N}-[(1~{S},2~{R})-2-[(4-bromanyl-2-morpholin-4-ylcarbonyl-6-nitro-phenyl)amino]cyclohexyl]-2-oxidanylidene-1~{H}-quinoline-4-carboxamide | | Authors: | Nie, T.Q, Su, H.X, Li, M.J, Xu, Y.C. | | Deposit date: | 2024-01-30 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-26 | | Method: | X-RAY DIFFRACTION (1.91 Å) | | Cite: | Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CL pro Inhibitors as anti-SARS-CoV-2 Drug Candidate.
J.Med.Chem., 67, 2024
|
|
8Z6Q
 | |
8Z6S
 | |
8Z6U
 | |
8Z6W
 | |
8Z86
 | | BA.5 RBD in complex with CR9 | | Descriptor: | CR9 heavy chain, CR9 light chain, Spike protein S1 | | Authors: | Feng, L.L. | | Deposit date: | 2024-04-21 | | Release date: | 2025-02-12 | | Last modified: | 2025-06-18 | | Method: | ELECTRON MICROSCOPY (3.87 Å) | | Cite: | A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5.
Signal Transduct Target Ther, 10, 2025
|
|
9BNT
 | | Crystal Structure of T21I SARS-CoV-2 Main Protease | | Descriptor: | 3C-like proteinase | | Authors: | Papini, C, Anderson, K.S. | | Deposit date: | 2024-05-03 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (1.83 Å) | | Cite: | Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M pro ) with Noncovalent Preclinical Candidate, Mpro61.
Acs Bio Med Chem Au, 5, 2025
|
|
9BNU
 | | Crystal Structure of T190I SARS-CoV-2 Main Protease | | Descriptor: | 3C-like proteinase nsp5 | | Authors: | Papini, C, Anderson, K.S. | | Deposit date: | 2024-05-03 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (1.55 Å) | | Cite: | Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M pro ) with Noncovalent Preclinical Candidate, Mpro61.
Acs Bio Med Chem Au, 5, 2025
|
|
9BNV
 | |
9BNW
 | |
9BNX
 | |
9BNY
 | |
9BNZ
 | |
9BO0
 | | Crystal Structure of T21I SARS-CoV-2 Main Protease in Complex with Compound Mpro61 | | Descriptor: | (5P)-5-[(1P,3M,3'P)-3-{3-chloro-5-[(2-chlorophenyl)methoxy]-4-fluorophenyl}-2-oxo-2H-[1,3'-bipyridin]-5-yl]-1-methylpyrimidine-2,4(1H,3H)-dione, 3C-like proteinase | | Authors: | Papini, C, Zhang, C.H, Jorgensen, W.L, Anderson, K.S. | | Deposit date: | 2024-05-03 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.16 Å) | | Cite: | Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M pro ) with Noncovalent Preclinical Candidate, Mpro61.
Acs Bio Med Chem Au, 5, 2025
|
|
9BO1
 | | Crystal Structure of T190I SARS-CoV-2 Main Protease in Complex with Compound Mpro61 | | Descriptor: | (5P)-5-[(1P,3M,3'P)-3-{3-chloro-5-[(2-chlorophenyl)methoxy]-4-fluorophenyl}-2-oxo-2H-[1,3'-bipyridin]-5-yl]-1-methylpyrimidine-2,4(1H,3H)-dione, 3C-like proteinase nsp5 | | Authors: | Papini, C, Zhang, C.H, Jorgensen, W.L, Anderson, K.S. | | Deposit date: | 2024-05-03 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (1.96 Å) | | Cite: | Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M pro ) with Noncovalent Preclinical Candidate, Mpro61.
Acs Bio Med Chem Au, 5, 2025
|
|
9BO2
 | | Crystal Structure of A173V/L50F SARS-CoV-2 Main Protease in Complex with Compound Mpro61 | | Descriptor: | (5P)-5-[(1P,3M,3'P)-3-{3-chloro-5-[(2-chlorophenyl)methoxy]-4-fluorophenyl}-2-oxo-2H-[1,3'-bipyridin]-5-yl]-1-methylpyrimidine-2,4(1H,3H)-dione, 3C-like proteinase nsp5 | | Authors: | Papini, C, Kenneson, J, Zhang, C.H, Jorgensen, W.L, Anderson, K.S. | | Deposit date: | 2024-05-03 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (1.91 Å) | | Cite: | Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M pro ) with Noncovalent Preclinical Candidate, Mpro61.
Acs Bio Med Chem Au, 5, 2025
|
|
9BO3
 | | Crystal Structure of E166V SARS-CoV-2 Main Protease in Complex with Compound Mpro61 | | Descriptor: | (5P)-5-[(1P,3M,3'P)-3-{3-chloro-5-[(2-chlorophenyl)methoxy]-4-fluorophenyl}-2-oxo-2H-[1,3'-bipyridin]-5-yl]-1-methylpyrimidine-2,4(1H,3H)-dione, 3C-like proteinase nsp5 | | Authors: | Papini, C, Kenneson, J, Zhang, C.H, Jorgensen, W.L, Anderson, K.S. | | Deposit date: | 2024-05-03 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.78 Å) | | Cite: | Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M pro ) with Noncovalent Preclinical Candidate, Mpro61.
Acs Bio Med Chem Au, 5, 2025
|
|
9BO4
 | | Crystal Structure of T21I SARS-CoV-2 Main Protease in Complex with Nirmatrelvir | | Descriptor: | (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase | | Authors: | Papini, C, Anderson, K.S. | | Deposit date: | 2024-05-03 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.28 Å) | | Cite: | Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M pro ) with Noncovalent Preclinical Candidate, Mpro61.
Acs Bio Med Chem Au, 5, 2025
|
|
9BO5
 | | Crystal Structure of T190I SARS-CoV-2 Main Protease in Complex with Nirmatrelvir | | Descriptor: | (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase nsp5 | | Authors: | Papini, C, Anderson, K.S. | | Deposit date: | 2024-05-03 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (1.84 Å) | | Cite: | Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (M pro ) with Noncovalent Preclinical Candidate, Mpro61.
Acs Bio Med Chem Au, 5, 2025
|
|
